INTS - NASDAQ

Intensity Therapeutics, Inc.

INTS·NASDAQ

$1.32

+3.9E+2%

HealthcareBiotechnology

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$62.24M

EPS-0.1300

P/E Ratio-0.57

Earnings Date11/12/2025

4.78M

Assets

-72%

3Y-8.0%

5Y-46.0%

10Y-46.0%

1.86M

Total Liabilities

-55%

3Y-87.0%

5Y-84.0%

10Y-84.0%

2.92M

Total Equity

-78%

3Y-134.0%

5Y-223.0%

10Y-223.0%

Intensity Therapeutics, Inc. Funding & Solvency Profile

INTS · NASDAQ

Current Assets

Cash & Cash Equivalents2.59M

Net Receivables0.00

Inventory0.00

Other Current Assets0.00

Total Current Assets3 M

Non-Current Assets

Property, Plant & Equipment122.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.30M

Total Non-Current Assets1 M

Total Assets

4.78M

Financial Health Analysis

Current Ratio

1.92x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.64x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

2 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

70% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Intensity Therapeutics, Inc. Balance Sheet

INTS • NASDAQ

Intensity Therapeutics, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	2.6M	8.6M	1.3M	4.5M	9.3M	3.8M
Short-Term Investments	0.0	6.2M	0.0	0.0	0.0	4.6M
Cash & Short-Term Investments	2.6M	14.8M	1.3M	4.5M	9.3M	8.4M
Net Receivables	0.0	0.0	62.3K	51.3K	67.8K	33.6K
Other Receivables	0.0	0.0	62.3K	51.3K	67.8K	21.9K
Inventory	0.0	0.0	29.4K	70.4K	217.2K	205.5K
Prepaids	773K	682K	63K	70.4K	67.2K	55.5K
Other Current Assets	0.0	6K	-16.2K	-1.2K	-40.3K	-39K
Total Current Assets	3.4M	15.5M	1.5M	4.7M	9.6M	8.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	122K	147K	139.1K	318.1K	490.2K	252.7K
Long-Term Investments	0.0	0.0	0.0	0.0	50K	75K
Other Non-Current Assets	1.3M	1.7M	167.7K	167.7K	-18.3K	-45.6K
Total Non-Current Assets	1.4M	1.8M	306.8K	485.9K	521.9K	282.1K
Total Assets	4.8M	17.3M	1.8M	5.2M	10.1M	8.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.2M	3M	603K	172.5K	222.7K	394K
Accounts Payable	1.2M	3M	603K	172.5K	222.7K	394K
Accrued Expenses	452K	392K	1.7M	1.3M	952K	617.1K
Short Term Debt	0.0	0.0	4.3M	2M	171.2K	0.0
Capital Lease Obligations (Current)	28K	20K	143K	182.3K	171.2K	117.2K
Other Current Liabilities	56K	499K	-655.0	0.0	-171.2K	0.0
Total Current Liabilities	1.8M	4M	6.8M	3.7M	1.3M	1.1M
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	0.0	36K	10M	10M	10M	10M
Total Non-Current Liabilities	110K	174K	10M	10.2M	10.4M	10.2M
Capital Lease Obligations	138K	158K	143.2K	325.9K	497.5K	260.3K
Total Liabilities	1.9M	4.1M	16.9M	13.9M	11.7M	11.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	17.3M	325.0	10M	325.0	215.0
Common Stock	2K	1K	341.0	682.0	682.0	681.0
Additional Paid-In Capital	69.7M	63.7M	23.6M	22.4M	21.7M	14.8M
Retained Earnings	-66.8M	-50.5M	-38.7M	-31.1M	-23.2M	-17.1M
Accumulated Other Comprehensive Income/Loss	0.0	-17.3M	0.0	-31.1M	0.0	-17.1M
Other Total Stockholders' Equity	0.0	0.0	826.0	341.0	-50K	17.1M
Total Stockholders' Equity	2.9M	13.2M	-15.1M	-8.7M	-1.6M	-2.4M
Total Equity	2.9M	13.2M	-15.1M	-8.7M	-1.6M	-2.4M
SUMMARY
Total Liabilities & Equity	4.8M	17.3M	1.8M	5.2M	10.1M	8.9M
Total Investments	0.0	6.2M	0.0	0.0	50K	4.6M
Total Debt	138K	158K	4.5M	2.3M	497.5K	260.3K
Net Debt	-2.5M	-8.4M	3.2M	-2.2M	-8.8M	-3.6M
Shares Outstanding	47,148,936	47,148,936	47,148,936	47,148,936	47,148,936	47,148,936

SEC Filings

INTS - Filing history and reports

No SEC filings available for INTS

Related Guides

Blog Categories

Continue your INTS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.